KCRS21 Presentations & Video

2021 Kidney Cancer Research Summit

Program content is now LIVE! View the program presentations, including video and slides, using the interactive program below.

Each video is the full session length; to jump to a particular presentation, note the timestamp in red beneath the speaker’s name.

To view slide presentations, click the     icon next to the presentation title.

Welcome and Fireside Chat with Gordon Freeman and Arlene Sharpe

Bryan Lewis, KidneyCAN President
Toni Choueiri, KCRS Co-Chair, Dana-Farber Cancer Institute
Hans Hammers, KCRS Co-Chair, University of Texas Southwestern.

Our Lives with Immunology
Gordon Freeman, Dana-Farber Cancer Institute
Arlene Sharpe, Harvard Medical School
(begins at 4:55)

Tumor evolution/mechanisms of lethality

Moderated by Scott Tykodi, UW Medicine & Eric Jonasch, MDACC

  Targeting the Osteogenic Niche for Preventing Kidney Cancer Bone Metastasis Progression
– Robert Satcher, M.D. Anderson Cancer Center
(begins at 1:40)

  Epigenetic Modifications of Cytosines in Clear Cell Kidney Carcinogenesis and Survival
– Lucas Salas, Dartmouth College
(begins at 14:43)

  Analysis of Transcriptional Profiles During the Evolution of ccRCC from Premalignant to Malignant Lesions
– Olivia Lombardi, University of Oxford
(begins at 28:43)

  Dissecting the Periostin-Directed Metastatic Cross Talk in Clear Cell Renal Cell Carcinoma
– Lily Wu, University of California, Los Angeles
(begins at 45:55)

Innovative non-immune therapy related therapeutics and monitoring

Moderated by Eric Jonasch, MDACC & Moshe Ornstein, Cleveland Clinic

  The Investigation of Ferroptosis as a Novel Therapeutic Paradigm for Kidney Cancer
– Mei Yee Koh, Kuda Therapeutics, Inc.

(begins at 1:42)

  Exploiting Cholesterol Metabolism to Treat Primary and Metastatic Renal Carcinoma
– M. Celeste Simon, University of Pennsylvania
(begins at 16:40)

  Monitoring Disease Burden and Biology Using Tumor Cell-Free DNA in Metastatic Kidney Cancer
– Scott Haake, Vanderbilt University Medical Center
(begins at 31:27)

 Exploiting Epigenetic Dysregulation to Identify Targetable Vulnerabilities in ccRCC
– Abhishek Chakraborty, Cleveland Clinic Foundation
(begins at 47:24)

Non-Clear Cell RCC

Moderated by Nizar Tannir, MDACC & Ari Hakimi, MSKCC

  Development of Mouse Models for Variant RCC Histologies
– Giannicola Genovese, MD Anderson Cancer Center
(begins at 2:06)

  Unlocking the Human Relevance of a New Genetic Papillary Renal Cell Carcinoma Mouse Model
– Richard Link, Baylor College of Medicine
(begins at 10:56)

  The Pathogenesis and Therapy of Chromophobe Renal Cell Carcinoma
– Elizabeth Henske, Brigham and Women’s Hospital
(begins at 20:20)

  Genomic and Functional Analysis of Translocation Renal Cell Carcinoma
– Srinivas Viswanathan, Dana-Farber Cancer Institute
(begins at 26:28)

  A Novel Mechanism of Pathogenesis for Renal Medullary Carcinoma
– Pavlos Msaouel, MD Anderson Cancer Center
(begins at 34:10)

Immunotherapy Advances and Research

Moderated by Hans Hammers, UTSW & Michael Atkins, GLCCC

  Immunotherapy Based Biomarkers that Could Relate or Inspire RCC Research
– Janis Taube, Johns Hopkins University
(begins at 13:00)

  Understanding CD8+ T-Cell Specificity and Function in Renal Cell Carcinoma
– David Braun, Dana-Farber Cancer Institute
(begins at 35:15)

  Integrated Analysis of Somatic Genomic Mutations and Antigen Presentation as Predictive Biomarkers for Combination Immunotherapy in Kidney Cancer
– Chung-Han Lee, Memorial Sloan Kettering Cancer Center
(begins at 50:51)

  Combining Locally Administered Ipilimumab with a Personalized Neoantigen Cancer Vaccine to Improve T-Cell Priming and Antitumor Immunity in High-Risk Renal Cell Carcinoma
– Catherine Wu, Dana-Farber Cancer Institute
(begins at 1:04:04)

  Overcoming Kidney Cancer Resistance to Immune Checkpoint Inhibitors
– Kiyoshi Ariizumi, UT Southwestern Medical Center
(begins at 1:21:49)

Clinical and Scientific Updates in Kidney Cancer

Moderated by Toni Choueiri, DFCI & Brian Rini, VUMC

  Recent Clinical Trial Results
– Elizabeth Plimack, Fox Chase Cancer Center
(begins at 0:46)

  Translational Research Updates in Renal Cancer
– Tom Powles, Barts Cancer Centre
(begins at 19:30)

  Trials in Progress and Their Significance
– Robert Motzer, Memorial Sloan Kettering Cancer Center
(begins at 43:00)

Abstract Oral Presentations

Moderated by Sumanta Pal, CHCCC & Rana McKay, UC San Diego

 

  A phase 3 trial of lenvatinib plus pembrolizumab versus sunitinib as a first-line treatment for patients with advanced renal cell carcinoma: overall survival follow-up analysis (the CLEAR study)
– Toni Choueiri, Dana-Farber Cancer Institute
(begins at 0:29)

  Characterization of responders in the phase 3 CheckMate 9ER trial: nivolumab plus cabozantinib versus sunitinib in patients with previously untreated advanced renal cell carcinoma
– Amishi Shah, MD Anderson Cancer Center
(begins at 11:22)

  Pembrolizumab (pembro) vs placebo as post nephrectomy adjuvant therapy for patients with renal cell carcinoma (RCC): randomized, double-blind, phase 3 KEYNOTE-564 study
Toni Choueiri, Dana-Farber Cancer Institute and presented by Tom Powles, Barts Cancer Centre
(begins at 26:00)

  Nivolumab/ipilimumab with or without CBM588 in metastatic renal cell carcinoma: a randomized phase Ib study and in-depth analysis of gut microbiome evolution
– Nazli Dizman, Yale New Haven Hospital
(begins at 36:50)

  Integrative Clinical and Molecular Characterization of Translocation Renal Cell Carcinoma
– Ziad Bakouny, Dana-Farber Cancer Institute
(begins at 44:39)

  Generation of an in vivoCRISPR/Cas9-based ccRCC model using AAV
– Laura Stransky, Dana-Farber Cancer Institute
(begins at 59:33)

Abstract Rapid Presentations

Moderated by Sumanta Pal, CHCCC & Rana McKay, UC San Diego

 

  Potential Role of Seleno-L-Methionine (SLM) in Stabilization of Tumor Vasculature and Enhanced Efficacy of Axitinib in Previously Treated Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
– Yousef Zakharia, University of Iowa
(begins at 0:40)

  Real-world treatment patterns and outcomes of front-line axitinib plus pembrolizumab versus ipilimumab plus nivolumab for metastatic clear cell renal cell carcinoma
– Kevin Zarrabi, Fox Chase Cancer Center
(begins at 7:55)

  Characterizing the immune response in patients with renal cell carcinoma (RCC) following COVID-19 vaccination
– Jasnoor Malhotra, City of Hope Comprehensive Cancer Center
(begins at 14:25)

  Histologic Growth Patterns in Nephrectomy Specimens of Clear Cell Renal Cell Carcinoma Inform Tumor Evolution
– Nicolas Sayegh, Huntsman Cancer Institute
(begins at 18:33)

  Transcriptomic analysis predicts resistance and toxicity in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI)
– Lucia Carril-Ajuria, University Hospital 12 de Octubre
(begins at 29:15)

  Ultra-sensitive ctDNA distinguishes complete response (CR) and partial response (PR) with immunotherapy in metastatic renal cell carcinoma (mRCC) patients
– Alex Chehrazi-Raffle, City of Hope Comprehensive Cancer Center
(begins at 34:50)

  Seq-ing the source of radiation-induced anti-tumor immunogenicity in renal cell carcinoma patient tumors
– Jason Muhitch, Roswell Park Comprehensive Cancer Center
(begins at 40:29)

  Multiplex analysis of the tumor microenvironment (TME) in papillary renal cell carcinoma (pRCC) suggests a role of macrophages in therapeutic response
– Nicholas Salgia, University at Buffalo
(begins at 46:07)

KidneyCAN's mission is to accelerate cures for kidney cancer.
LEARN MORE

KidneyCAN is a registered 501(c)(3) nonprofit grassroots organization dedicated to funding and finding a cure for kidney cancer.

KidneyCAN Platinum Guidestar Seal

Contact KidneyCAN

For general inquiries regarding KCRS sponsorship, registration, or event logistics, please contact KidneyCAN office manager Angie Edwards at [email protected].

Kidney Cancer Coalition | 8327 Germantown Avenue | Philadelphia | PA 19118